In the two cases presented in this report, we observed that the integration of albuvirtide into existing antiretroviral regimens resulted in successful viral suppression, accompanied by CD4 + T cell count improvements despite concurrent immunosuppressive cancer therapy. Here, CD4 is linked to cancer.